Drug intelligence / Profile preview

SG002

Development stage: Preclinical
Lead developer: Shenji Changhua Biotechnology
Modality: Gene Therapies

Overview

SG002 is an adeno-associated virus (AAV)-based gene therapy being developed by Shenji Changhua for the treatment of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The therapy utilizes an AAV vector to deliver a genetic payload to the central nervous system, though the specific molecular target and mechanism of action have not been publicly disclosed. It is currently in the preclinical stage of development, targeting the shared underlying pathology of ALS and FTD.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on SG002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SG002.

Explore the full profile